Bullish & Foolish
Full ENVB fundamentals All 466 on the Survival Watch

ENVBENVERIC BIOSCIENCES, INC.

Is Enveric Biosciences struggling financially?

Yes, by its own account. Enveric Biosciences told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$6.4M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash burned over the last 12 months

$15.1M

What Enveric Biosciences told the SEC

…has incurred continuing losses from its operations. The Company’s operations have been funded principally through the issuance of equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements. In assessing the Company’s ability to continue as a going concern, the…

ENVERIC BIOSCIENCES, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 25.2% share-count increase The company issued stock. Each share now owns 20.1% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt